Allergan’s unusual arrangement to try to avoid IPR proceedings on Restasis made headlines last week. Our article suggesting the move is potentially damaging for the image of the biopharma sector as a whole prompted a response from Acorda CEO Ron Cohen.
Allergan PLC’s transfer of patent rights on Restatis to the St. Regis Mohawk tribe has brought renewed attention to the biopharma industry’s concerns about the inter partes review (IPR) patent review process.
In an earlier article, we offered a view that Allergan’s move is likely to backfire, at least if the broader...
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
